Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting
Go back to Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting| (NASDAQ: MRNS) | Delayed: 0.55 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.55 | 52 Week High | $8.12 | |||
| Open | $0.55 | 52 Week Low | $1.02 | |||
| Day High | $0.55 | P/E | N/A | |||
| Day Low | $0.55 | EPS | $0.00 | |||
| Volume | 998 | |||||

